Klin Onkol 2009; 22(6): 273-277.
Summary
Backgrounds: Primary debulking surgery and chemotherapy (paclitaxel and carboplatin) remain the standard treatment for advanced ovarian
cancer. The size of the residual tumour after primary debulking surgery has proved to be an important prognostic determinant. Complete tumour
debulking without any macroscopic residual disease is considered the optimal primary debulking surgery. It is not possible to perform such an
aggressive operation in patients with advanced ovarian cancer due to the bad performance status and extensive disease. Neo‑adjuvant chemotherapy
and interval debulking surgery seem to be an effective treatment strategy in this group of patients. Material and Methods: The retrospective
analysis evaluated the efficiency of interval debulking surgery in correlation with progression‑free and overall survival in patients with advanced
ovarian cancer. 38 patients were treated with standard chemotherapy: paclitaxel 175 mg/ m2 and carboplatin 5–6 AUC every three weeks. According
to the clinical response, surgical debulking was considered, after which postoperative chemotherapy was given. Ineligible patients for interval
debulking were treated with 2nd line chemotherapy. Results: After neo‑ adjuvant chemotherapy, 24 patients of the group of 38 achieved partial
remission and interval debulking surgery was indicated. Optimal interval debulking surgery was performed in 12 patients, suboptimal debulking
surgery in 12 patients. Of the entire group, 14 patients did not show any adequate response to the primary treatment, they did not have interval
debulking surgery indicated and they were treated with 2nd line chemotherapy. Progression‑free survival in patients after optimal debulking was
11 months, median overall survival was not achieved (OS > 42.5 months). Progression‑free survival in patients after suboptimal debulking was
6 months and median overall survival was 33 months. Median overall survival in patients without surgical treatment was 21.5 months. Conclusion:
The results of the study confirm that neo‑adjuvant chemotherapy with subsequent interval debulking surgery is a suitable therapeutic approach in
primary inoperable patients with advanced ovarian cancer.
